A five-year evaluation of reports of overdose with indinavir sulfate

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 6, 2003, Pages 449-457

  Lehman, Heidi P ^a   Benson, Joan O ^a   Beninger, Paul R ^a   Anderson, Charles A ^a   Blumenthal, Steven J ^a   Sharrar, Robert G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adverse event; Antiretroviral therapy; Medication error; Overdose; Protease inhibitor

Indexed keywords

ACTIVATED CARBON; INDINAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLEEDING; CHILD; CONTROLLED STUDY; CONVALESCENCE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVALUATION; FEMALE; FLANK PAIN; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; KIDNEY COLIC; KIDNEY FAILURE; LICENSING; LONG TERM CARE; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; PSYCHOSIS;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MIDDLE AGED; OVERDOSE; SUICIDE;

EID: 0042262364     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.868     Document Type: Article

References (19)

1. Indinavir sulfate (package insert). Merck & Co., Inc.: West Point, PA, 2001.
2. Amprenavir (package insert). Glaxo Wellcome Inc.: Research Triangle Park, NC, 2001.
3. Saquinavir (package insert). Roche Pharmaceuticals: Nutley, NJ, 2000.
4. Ritonavir (package insert). Abbott Laboratories: North Chicago, IL, 2000.
5. Nelfinavir mesylate (package insert). Agouron Pharmaceuticals: La Jolla, CA, 2000.
6. Lopinavir/ritonavir (package insert). Abbott Laboratories: North Chicago, IL, 2001.
7. McGuire D, Marder K. Pharmacological frontiers in the treatment of AIDS dementia. J Psychopharmacol 2000; 14: 251-257.
8. Catalan J, Pugh K. Suicidal behavior and HIV infection-is there a link? AIDS Care 1995; 7(Suppl. 2): S117-S121.
9. Marzuk PM, Tardiff K, Leon A, et al. HIV seroprevalence among suicide victims in New York City, 1991-1993. Am J Psychiatry 1997; 154: 1720-1725.
10. Burkhart KK, Kemerer K, Donovan JW. Indinavir overdose. J Toxicol Clin Toxicol 1998; 36: 747.
11. Duval X, Peytavin G, Fouqueray B, Leport C, Vildé JL. Reninangiotensin system inhibition in a patient having an overdose of HIV protease inhibitor (letter). AIDS 1999; 13: 1983-1984.
12. Terragna A, Mazzarello G, Anselmo M, Canessa A, Rossi E. Suicidal attempts with zidovudine (letter). AIDS 1990; 4: 88.
13. Valentine C, Williams O, Davis A, et al. Case study of zidovudine overdose (letter). AIDS 1993; 7: 436-437.
14. Maignen F, Meglio S, Bidault I, Castot A. Acute toxicity of zidovudine: analysis of the literature and number of cases at the Paris Poison Control Center. Therapie 1993; 48: 129-131.
15. Balani SK, Woolf EJ, Hoagland VL, et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996; 24: 1389-1394.
16. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2710-2715.
17. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 2784-2791.
18. Anonymous. Lodenosine trial halted. AIDS Patient Care STDS 2000; 14: 61.
19. Institute of Medicine. To Err is Human: Building a Safer Health System, Kohn LT, Corrigan JM, Donaldson MS (eds). National Academy Press: Washington, DC, 2000.